NEATO-ROBOTICS
4.9.2020 13:32:20 CEST | Business Wire | Pressemeddelelse
Neato Robotics, en førende leverandør af intelligente robotstøvsugere til hjemmet, har i dag annonceret lanceringen af de nye modeller i deres kvalitetsserie – Neato D10, D9 og D8 – på IFA Berlin 2020. Neato-robotstøvsugere er den ultimative partner inden for rengøring, idet de har den bedste teknologi i klassen, nem indstilling og hardware, der er skabt til at holde.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200904005047/da/
"Vi har kombineret Neatos 15 års erfaring i branchen med kundefeedback og de seneste nyskabelser inden for robotteknologi og kunstig intelligens, og vi er glade for at kunne introducere disse fantastiske nye produkter – vores bedste indtil nu – for hele verden. Neatos nye serie af intelligente robotstøvsugere er unik i design og teknologi, med en førsteklasses brugeroplevelse og en ny MyNeato-app, som viser vores forpligtelse til at gøre hverdagen nemmere med robotteknologi", siger Neatos CEO, Thomas Nedder.
De nye Neato-robotstøvsugere har kvalitet og brugeroplevelse, der er bedst i deres klasse, samtidig med, at deres D-formede design, som er det første af sin art i branchen, har fået et løft. Neato-ejere kan nå fra hjørne til hjørne og fra kant til kant og få en mere komplet rengøring ved at bruge den bredeste børste og den største støvbeholder på markedet. Neato har det første originale HEPA-filter, og Neato D10 opfanger op til 99,97 % allergener og partikler såsom støv og skæl helt ned til 0,3 my. Det har aldrig været nemmere at indstille en Neato, med en Bluetooth-aktiveret tilslutning til wi-fi og effektiviseret sekstrins-proces på vores nye MyNeato-app – den korteste indstillingsproces i branchen – for straks at komme i gang med rengøringen.
Neato D10
Med en køretid på op til 150 minutter, et originalt HEPA-filter til at opfange op til 99,97 % allergener så små som 0,3 my samt den seneste LaserSmartTM LIDAR-baserede teknologi, er Neato D10 ultraydeevnen til den ultimative rengøring.
Neato D9
Neato D9 gør det beskidte arbejde for dig. Med et ultraydende filter i HEPA-stil, der opfanger 99,5 % støv og allergener, en køretid på op til 120 minutter samt Neatos signatur-teknologi, LaserSmartTM , gør Neato rent når og hvor du ønsker det, også når det er mørkt.
Neato D8
Neato D8 leveres med branchens første signaturkvalitet og -teknologi, som du er vant til at forvente fra Neato – som fx den største støvbeholder, ekstra bred børste og den seneste LaserSmartTM -teknologi – med en bedre brugeroplevelse, en køretid på op til 90 minutter og forbedret effektiv rengøring.
Den nye produktserie vil være tilgængelig i efteråret 2020 hos vores detailhandlere i hele Nordamerika, Europa og Japan, samt i USA på NeatoRobotics.com .
Om Neato
Neato Robotics udvikler intelligente robotter til hjemmet for at gøre livet nemmere for folk og løse reelle problemer. Neato er engageret i at skabe en ægte brugerdefineret rengøringsoplevelse, hvor vi sikrer, at robotterne udvikles og tilpasses til forbrugeren. Neato driver innovation med intelligent LaserSmartTM LIDAR-baseret navigation, kortlægning, smart hjemmeopkobling og uovertruffen rengøringsteknologi. Få mere at vide på www.neatorobotics.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200904005047/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
